Chemicals
Showing 9001–9150 of 41137 results
-
AM1241 is a cannabinoid (CB) receptor agonist that is selective for CB2 over CB1 with Ki values of 7.1 and 580 nM for human recombinant receptors transfected into HEK and CHO cells, respectively, in a radioligand binding assay.{14812,14986} It is considered a protean agonist as it has neutral antagonist and partial agonist activity, depending on the assay utilized.{14812} It is also acts in a species-dependent manner in vitro, acting as an agonist at human CB2 receptors (EC50 = 190 nM) but an inverse agonist at rat and mouse CB2 receptors (EC50s = 216 and 463 nM, respectively).{18107} AM1241 produces antinociception to thermal stimuli in rat hindpaw. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630 (Item No. 10006974) but not by the CB1 receptor-selective antagonist AM251 (Item No. 71670). AM1241 is neuroprotective, preventing HIV-1 glycoprotein Gp120-induced apoptosis in primary human and murine neural progenitor cells and increasing cell survival and differentiation. It increases hippocampal neurogenesis and decreases astro- and gliogenesis in GFAP/Gp120 transgenic mice when administered at a dose of 10 mg/kg daily for ten days.{38336} AM1241 also delays motor impairment in a murine model of amytrophic lateral sclerosis (ALS).{38337}
Brand:CaymanSKU:10010118 - 10 mgAvailable on backorder
AM1241 is a cannabinoid (CB) receptor agonist that is selective for CB2 over CB1 with Ki values of 7.1 and 580 nM for human recombinant receptors transfected into HEK and CHO cells, respectively, in a radioligand binding assay.{14812,14986} It is considered a protean agonist as it has neutral antagonist and partial agonist activity, depending on the assay utilized.{14812} It is also acts in a species-dependent manner in vitro, acting as an agonist at human CB2 receptors (EC50 = 190 nM) but an inverse agonist at rat and mouse CB2 receptors (EC50s = 216 and 463 nM, respectively).{18107} AM1241 produces antinociception to thermal stimuli in rat hindpaw. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630 (Item No. 10006974) but not by the CB1 receptor-selective antagonist AM251 (Item No. 71670). AM1241 is neuroprotective, preventing HIV-1 glycoprotein Gp120-induced apoptosis in primary human and murine neural progenitor cells and increasing cell survival and differentiation. It increases hippocampal neurogenesis and decreases astro- and gliogenesis in GFAP/Gp120 transgenic mice when administered at a dose of 10 mg/kg daily for ten days.{38336} AM1241 also delays motor impairment in a murine model of amytrophic lateral sclerosis (ALS).{38337}
Brand:CaymanSKU:10010118 - 25 mgAvailable on backorder
AM1241 is a cannabinoid (CB) receptor agonist that is selective for CB2 over CB1 with Ki values of 7.1 and 580 nM for human recombinant receptors transfected into HEK and CHO cells, respectively, in a radioligand binding assay.{14812,14986} It is considered a protean agonist as it has neutral antagonist and partial agonist activity, depending on the assay utilized.{14812} It is also acts in a species-dependent manner in vitro, acting as an agonist at human CB2 receptors (EC50 = 190 nM) but an inverse agonist at rat and mouse CB2 receptors (EC50s = 216 and 463 nM, respectively).{18107} AM1241 produces antinociception to thermal stimuli in rat hindpaw. The antinociceptive actions of AM1241 were blocked by the CB2 receptor-selective antagonist AM630 (Item No. 10006974) but not by the CB1 receptor-selective antagonist AM251 (Item No. 71670). AM1241 is neuroprotective, preventing HIV-1 glycoprotein Gp120-induced apoptosis in primary human and murine neural progenitor cells and increasing cell survival and differentiation. It increases hippocampal neurogenesis and decreases astro- and gliogenesis in GFAP/Gp120 transgenic mice when administered at a dose of 10 mg/kg daily for ten days.{38336} AM1241 also delays motor impairment in a murine model of amytrophic lateral sclerosis (ALS).{38337}
Brand:CaymanSKU:10010118 - 5 mgAvailable on backorder
AM1248 is an adamantoylindole derivative with an N-methylpiperidin-2-ylmethyl substitution at the indole 1-position. It reportedly acts as a moderately potent agonist for both the central CB1 and peripheral CB2 cannabinoid receptors (Kis = 11.9 and 4.8 nM, respectively).{20430} A related compound, 1-pentyl-3-(1-adamantoyl)indole, along with another synthetic cannabinoid, AM679, was identified as having been sold as a cannabinoid herbal blend known as “smart products” in Hungary in 2011.{20431}
Brand:CaymanSKU:11282 - 10 mgAvailable on backorder
AM1248 is an adamantoylindole derivative with an N-methylpiperidin-2-ylmethyl substitution at the indole 1-position. It reportedly acts as a moderately potent agonist for both the central CB1 and peripheral CB2 cannabinoid receptors (Kis = 11.9 and 4.8 nM, respectively).{20430} A related compound, 1-pentyl-3-(1-adamantoyl)indole, along with another synthetic cannabinoid, AM679, was identified as having been sold as a cannabinoid herbal blend known as “smart products” in Hungary in 2011.{20431}
Brand:CaymanSKU:11282 - 25 mgAvailable on backorder
AM1248 is an adamantoylindole derivative with an N-methylpiperidin-2-ylmethyl substitution at the indole 1-position. It reportedly acts as a moderately potent agonist for both the central CB1 and peripheral CB2 cannabinoid receptors (Kis = 11.9 and 4.8 nM, respectively).{20430} A related compound, 1-pentyl-3-(1-adamantoyl)indole, along with another synthetic cannabinoid, AM679, was identified as having been sold as a cannabinoid herbal blend known as “smart products” in Hungary in 2011.{20431}
Brand:CaymanSKU:11282 - 5 mgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM2201 6-hydroxyindole metabolite is an expected metabolite of AM2201 generated during phase I metabolism by cytochrome P450, suggesting that it would be detectable in blood and urine.{19353} The biological properties of this compound are not known. This product is intended for forensic applications.
Brand:CaymanSKU:11192 - 1 mgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM2201 6-hydroxyindole metabolite is an expected metabolite of AM2201 generated during phase I metabolism by cytochrome P450, suggesting that it would be detectable in blood and urine.{19353} The biological properties of this compound are not known. This product is intended for forensic applications.
Brand:CaymanSKU:11192 - 5 mgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, respectively.{18696} AM 2201 7-hydroxyindole metabolite is an expected minor monohydroxylated urinary metabolite of AM2201, based on the known metabolism of similar compounds.{19353} Its biological actions are unknown.
Brand:CaymanSKU:11193 - 1 mgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, respectively.{18696} AM 2201 7-hydroxyindole metabolite is an expected minor monohydroxylated urinary metabolite of AM2201, based on the known metabolism of similar compounds.{19353} Its biological actions are unknown.
Brand:CaymanSKU:11193 - 5 mgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM2201 N-(2-fluoropentyl) isomer differs structurally from AM2201 by having fluorine at the 2 position rather than the 5 position of the pentyl chain. The physiological and toxicological properties of this compound have not been reported. This product is intended for forensic applications.
Brand:CaymanSKU:9001031 - 1 mgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM2201 N-(2-fluoropentyl) isomer differs structurally from AM2201 by having fluorine at the 2 position rather than the 5 position of the pentyl chain. The physiological and toxicological properties of this compound have not been reported. This product is intended for forensic applications.
Brand:CaymanSKU:9001031 - 100 µgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM2201 N-(2-fluoropentyl) isomer differs structurally from AM2201 by having fluorine at the 2 position rather than the 5 position of the pentyl chain. The physiological and toxicological properties of this compound have not been reported. This product is intended for forensic applications.
Brand:CaymanSKU:9001031 - 500 µgAvailable on backorder
AM 2201 N-(4-fluoropentyl) isomer is a derivative of AM2201, which is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} The physiological actions and metabolism of this isomer have not been characterized.
Brand:CaymanSKU:9001029 - 1 mgAvailable on backorder
AM 2201 N-(4-fluoropentyl) isomer is a derivative of AM2201, which is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} The physiological actions and metabolism of this isomer have not been characterized.
Brand:CaymanSKU:9001029 - 100 µgAvailable on backorder
AM 2201 N-(4-fluoropentyl) isomer is a derivative of AM2201, which is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} The physiological actions and metabolism of this isomer have not been characterized.
Brand:CaymanSKU:9001029 - 500 µgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively.{18696} AM2201 N-(4-hydroxypentyl) metabolite is an expected urinary metabolite of AM2201, based on the known metabolism of similar compounds.{19353} Its biological actions are unknown.
Brand:CaymanSKU:10203 - 1 mgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively.{18696} AM2201 N-(4-hydroxypentyl) metabolite is an expected urinary metabolite of AM2201, based on the known metabolism of similar compounds.{19353} Its biological actions are unknown.
Brand:CaymanSKU:10203 - 100 µgAvailable on backorder
AM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively.{18696} AM2201 N-(4-hydroxypentyl) metabolite is an expected urinary metabolite of AM2201, based on the known metabolism of similar compounds.{19353} Its biological actions are unknown.
Brand:CaymanSKU:10203 - 500 µgAvailable on backorder
AM2232 is a potent synthetic cannabinoid (CB) with Ki values of 0.28 and 1.48 nM for the CB1 and CB2 receptors, respectively.{18696} The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications.
Brand:CaymanSKU:11503 - 10 mgAvailable on backorder
AM2232 is a potent synthetic cannabinoid (CB) with Ki values of 0.28 and 1.48 nM for the CB1 and CB2 receptors, respectively.{18696} The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications.
Brand:CaymanSKU:11503 - 25 mgAvailable on backorder
AM2232 is a potent synthetic cannabinoid (CB) with Ki values of 0.28 and 1.48 nM for the CB1 and CB2 receptors, respectively.{18696} The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications.
Brand:CaymanSKU:11503 - 5 mgAvailable on backorder
AM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM).{20115} Most of the affinity towards the CB1 receptor resides within the (R)-enantiomer of AM2233, which exhibits a Ki value of 0.2 nM and has ~8-fold higher affinity for CB1 compared to WIN 55,212-2 (Ki = 1.6 nM).{20115} AM2233 was developed for use as a selective radioligand for mapping the distribution of the CB1 receptor in the brain.{20115} Recently, however, AM2233 has received attention as a cannabimimetic acquired for recreational use as a “legal high” replacement for restricted substances. This compound is intended for forensic and research applications.
Brand:CaymanSKU:11008 - 1 mgAvailable on backorder
AM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM).{20115} Most of the affinity towards the CB1 receptor resides within the (R)-enantiomer of AM2233, which exhibits a Ki value of 0.2 nM and has ~8-fold higher affinity for CB1 compared to WIN 55,212-2 (Ki = 1.6 nM).{20115} AM2233 was developed for use as a selective radioligand for mapping the distribution of the CB1 receptor in the brain.{20115} Recently, however, AM2233 has received attention as a cannabimimetic acquired for recreational use as a “legal high” replacement for restricted substances. This compound is intended for forensic and research applications.
Brand:CaymanSKU:11008 - 10 mgAvailable on backorder
AM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM).{20115} Most of the affinity towards the CB1 receptor resides within the (R)-enantiomer of AM2233, which exhibits a Ki value of 0.2 nM and has ~8-fold higher affinity for CB1 compared to WIN 55,212-2 (Ki = 1.6 nM).{20115} AM2233 was developed for use as a selective radioligand for mapping the distribution of the CB1 receptor in the brain.{20115} Recently, however, AM2233 has received attention as a cannabimimetic acquired for recreational use as a “legal high” replacement for restricted substances. This compound is intended for forensic and research applications.
Brand:CaymanSKU:11008 - 25 mgAvailable on backorder
AM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM).{20115} Most of the affinity towards the CB1 receptor resides within the (R)-enantiomer of AM2233, which exhibits a Ki value of 0.2 nM and has ~8-fold higher affinity for CB1 compared to WIN 55,212-2 (Ki = 1.6 nM).{20115} AM2233 was developed for use as a selective radioligand for mapping the distribution of the CB1 receptor in the brain.{20115} Recently, however, AM2233 has received attention as a cannabimimetic acquired for recreational use as a “legal high” replacement for restricted substances. This compound is intended for forensic and research applications.
Brand:CaymanSKU:11008 - 5 mgAvailable on backorder
AM2233 (Item No. 11008) is a synthetic cannabinoid (CB) which acts as a full agonist of the central CB1 receptor (Ki = 2.8 nM).{20115} AM2233 azepane isomer is an isomer of AM2233 in which the piperidine group has been replaced with azepane. The physiological and toxicological properties of this compound have not been explored. This product is intended for forensic and research applications.
Brand:CaymanSKU:11584 - 1 mgAvailable on backorder
AM2233 (Item No. 11008) is a synthetic cannabinoid (CB) which acts as a full agonist of the central CB1 receptor (Ki = 2.8 nM).{20115} AM2233 azepane isomer is an isomer of AM2233 in which the piperidine group has been replaced with azepane. The physiological and toxicological properties of this compound have not been explored. This product is intended for forensic and research applications.
Brand:CaymanSKU:11584 - 10 mgAvailable on backorder
AM2233 (Item No. 11008) is a synthetic cannabinoid (CB) which acts as a full agonist of the central CB1 receptor (Ki = 2.8 nM).{20115} AM2233 azepane isomer is an isomer of AM2233 in which the piperidine group has been replaced with azepane. The physiological and toxicological properties of this compound have not been explored. This product is intended for forensic and research applications.
Brand:CaymanSKU:11584 - 5 mgAvailable on backorder
AM2394 is an activator of glucokinase with an EC50 value of 60 nM in an enzyme assay in the presence of glucose.{52555} Oral administration of AM2394 (3-30 mg/kg) decreases plasma glucose levels in an oral glucose tolerance test in an ob/ob mouse model of diabetes.
Brand:CaymanSKU:20992 -Out of stock
AM2394 is an activator of glucokinase with an EC50 value of 60 nM in an enzyme assay in the presence of glucose.{52555} Oral administration of AM2394 (3-30 mg/kg) decreases plasma glucose levels in an oral glucose tolerance test in an ob/ob mouse model of diabetes.
Brand:CaymanSKU:20992 -Out of stock
AM2394 is an activator of glucokinase with an EC50 value of 60 nM in an enzyme assay in the presence of glucose.{52555} Oral administration of AM2394 (3-30 mg/kg) decreases plasma glucose levels in an oral glucose tolerance test in an ob/ob mouse model of diabetes.
Brand:CaymanSKU:20992 -Out of stock
AM2394 is an activator of glucokinase with an EC50 value of 60 nM in an enzyme assay in the presence of glucose.{52555} Oral administration of AM2394 (3-30 mg/kg) decreases plasma glucose levels in an oral glucose tolerance test in an ob/ob mouse model of diabetes.
Brand:CaymanSKU:20992 -Out of stock
AM251 is a cannabinoid (CB) receptor 1 antagonist.{9721} It binds to CB1 receptors in rat forebrain membrane preparations (Ki = 7.5 nM) and is selective over CB2 receptors in mouse spleen preparations (Ki = 2,290 nM) in radioligand binding assays. AM251 inhibits GTPγS binding induced by the CB receptor agonist CP 55,940 in HEK293 cells expressing human CB1 receptors (EC50 = 8 nM).{17583} AM251 (10 mg/kg) decreases immobility time in the forced swim test in wild-type but not CB1 receptor-deficient mice.{38334} It reduces fasting-induced food intake and body weight gain in mice when administered at a dose of 30 mg/kg. AM251 also induces GTPγS binding in HEK293 cells expressing the orphan receptor GPR55 (EC50 = 39 nM) and potentiates GABA-induced GABAA receptor currents (EC50 = 0.4 µM).{17583,38332} It prevents TGF-β1-induced epithelial-to-mesenchymal transition (EMT), inhibits SMAD2/3 and p38 MAPK activation, and reduces the expression of EMT-related transcription factors in HK-2 renal tubule epithelial cells.{38335} AM251 induces cell cycle arrest at the G2/M phase and apoptosis in A375 human melanoma cells.{38333}
Brand:CaymanSKU:71670 - 10 mgAvailable on backorder
AM251 is a cannabinoid (CB) receptor 1 antagonist.{9721} It binds to CB1 receptors in rat forebrain membrane preparations (Ki = 7.5 nM) and is selective over CB2 receptors in mouse spleen preparations (Ki = 2,290 nM) in radioligand binding assays. AM251 inhibits GTPγS binding induced by the CB receptor agonist CP 55,940 in HEK293 cells expressing human CB1 receptors (EC50 = 8 nM).{17583} AM251 (10 mg/kg) decreases immobility time in the forced swim test in wild-type but not CB1 receptor-deficient mice.{38334} It reduces fasting-induced food intake and body weight gain in mice when administered at a dose of 30 mg/kg. AM251 also induces GTPγS binding in HEK293 cells expressing the orphan receptor GPR55 (EC50 = 39 nM) and potentiates GABA-induced GABAA receptor currents (EC50 = 0.4 µM).{17583,38332} It prevents TGF-β1-induced epithelial-to-mesenchymal transition (EMT), inhibits SMAD2/3 and p38 MAPK activation, and reduces the expression of EMT-related transcription factors in HK-2 renal tubule epithelial cells.{38335} AM251 induces cell cycle arrest at the G2/M phase and apoptosis in A375 human melanoma cells.{38333}
Brand:CaymanSKU:71670 - 100 mgAvailable on backorder
AM251 is a cannabinoid (CB) receptor 1 antagonist.{9721} It binds to CB1 receptors in rat forebrain membrane preparations (Ki = 7.5 nM) and is selective over CB2 receptors in mouse spleen preparations (Ki = 2,290 nM) in radioligand binding assays. AM251 inhibits GTPγS binding induced by the CB receptor agonist CP 55,940 in HEK293 cells expressing human CB1 receptors (EC50 = 8 nM).{17583} AM251 (10 mg/kg) decreases immobility time in the forced swim test in wild-type but not CB1 receptor-deficient mice.{38334} It reduces fasting-induced food intake and body weight gain in mice when administered at a dose of 30 mg/kg. AM251 also induces GTPγS binding in HEK293 cells expressing the orphan receptor GPR55 (EC50 = 39 nM) and potentiates GABA-induced GABAA receptor currents (EC50 = 0.4 µM).{17583,38332} It prevents TGF-β1-induced epithelial-to-mesenchymal transition (EMT), inhibits SMAD2/3 and p38 MAPK activation, and reduces the expression of EMT-related transcription factors in HK-2 renal tubule epithelial cells.{38335} AM251 induces cell cycle arrest at the G2/M phase and apoptosis in A375 human melanoma cells.{38333}
Brand:CaymanSKU:71670 - 5 mgAvailable on backorder
AM251 is a cannabinoid (CB) receptor 1 antagonist.{9721} It binds to CB1 receptors in rat forebrain membrane preparations (Ki = 7.5 nM) and is selective over CB2 receptors in mouse spleen preparations (Ki = 2,290 nM) in radioligand binding assays. AM251 inhibits GTPγS binding induced by the CB receptor agonist CP 55,940 in HEK293 cells expressing human CB1 receptors (EC50 = 8 nM).{17583} AM251 (10 mg/kg) decreases immobility time in the forced swim test in wild-type but not CB1 receptor-deficient mice.{38334} It reduces fasting-induced food intake and body weight gain in mice when administered at a dose of 30 mg/kg. AM251 also induces GTPγS binding in HEK293 cells expressing the orphan receptor GPR55 (EC50 = 39 nM) and potentiates GABA-induced GABAA receptor currents (EC50 = 0.4 µM).{17583,38332} It prevents TGF-β1-induced epithelial-to-mesenchymal transition (EMT), inhibits SMAD2/3 and p38 MAPK activation, and reduces the expression of EMT-related transcription factors in HK-2 renal tubule epithelial cells.{38335} AM251 induces cell cycle arrest at the G2/M phase and apoptosis in A375 human melanoma cells.{38333}
Brand:CaymanSKU:71670 - 50 mgAvailable on backorder
AM281 is a potent and selective central cannabinoid (CB1) receptor antagonist/inverse agonist (Kis = 12 nM and 4,200 nM for CB1 and CB2, respectively).{13046,21749} Structurally, it is an analog of the CB1 inverse agonist rimonabant (Item No. 9000484).{21749} It has no effect on the vanilloid TRPV1 receptor.{12165} AM281 has been used to evaluate the potential effects of compounds at CB1.{13244,21496} It has also been used to study the membrane localization and cycling of CB1.{13567}
Brand:CaymanSKU:10006972 - 1 mgAvailable on backorder
AM281 is a potent and selective central cannabinoid (CB1) receptor antagonist/inverse agonist (Kis = 12 nM and 4,200 nM for CB1 and CB2, respectively).{13046,21749} Structurally, it is an analog of the CB1 inverse agonist rimonabant (Item No. 9000484).{21749} It has no effect on the vanilloid TRPV1 receptor.{12165} AM281 has been used to evaluate the potential effects of compounds at CB1.{13244,21496} It has also been used to study the membrane localization and cycling of CB1.{13567}
Brand:CaymanSKU:10006972 - 10 mgAvailable on backorder
AM281 is a potent and selective central cannabinoid (CB1) receptor antagonist/inverse agonist (Kis = 12 nM and 4,200 nM for CB1 and CB2, respectively).{13046,21749} Structurally, it is an analog of the CB1 inverse agonist rimonabant (Item No. 9000484).{21749} It has no effect on the vanilloid TRPV1 receptor.{12165} AM281 has been used to evaluate the potential effects of compounds at CB1.{13244,21496} It has also been used to study the membrane localization and cycling of CB1.{13567}
Brand:CaymanSKU:10006972 - 5 mgAvailable on backorder
Oleoyl ethanolamide (OEA) is an endogenous agonist for proliferator-activated receptor α (PPARα) that suppresses food intake, promotes lipolysis, and reduces weight gain in rodents. The biological effects of OEA are terminated by fatty-acid amide hydrolase and N-acylethanolamine-hydrolyzing acid amidase. AM3102 is an OEA analog that stimulates PPARα transcriptional activity with an EC50 value of 100 nM and prolongs feeding latency in rodents with an ED50 value of 2.4 mg/kg.{17364} It is resistant to enzymatic hydrolysis and is as potent as OEA in enhancing transcriptional activity of PPARα and reducing food intake in free-feeding rats.{17364,15762} AM3102 demonstrates weak affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with Ki values of 33 and 26 µM, respectively.{7422}
Brand:CaymanSKU:- Oleoyl ethanolamide (OEA) is an endogenous agonist for proliferator-activated receptor α (PPARα) that suppresses food intake, promotes lipolysis, and reduces weight gain in rodents. The biological effects of OEA are terminated by fatty-acid amide hydrolase and N-acylethanolamine-hydrolyzing acid amidase. AM3102 is an OEA analog that stimulates PPARα transcriptional activity with an EC50 value of 100 nM and prolongs feeding latency in rodents with an ED50 value of 2.4 mg/kg.{17364} It is resistant to enzymatic hydrolysis and is as potent as OEA in enhancing transcriptional activity of PPARα and reducing food intake in free-feeding rats.{17364,15762} AM3102 demonstrates weak affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with Ki values of 33 and 26 µM, respectively.{7422}
Brand:CaymanSKU:- Oleoyl ethanolamide (OEA) is an endogenous agonist for proliferator-activated receptor α (PPARα) that suppresses food intake, promotes lipolysis, and reduces weight gain in rodents. The biological effects of OEA are terminated by fatty-acid amide hydrolase and N-acylethanolamine-hydrolyzing acid amidase. AM3102 is an OEA analog that stimulates PPARα transcriptional activity with an EC50 value of 100 nM and prolongs feeding latency in rodents with an ED50 value of 2.4 mg/kg.{17364} It is resistant to enzymatic hydrolysis and is as potent as OEA in enhancing transcriptional activity of PPARα and reducing food intake in free-feeding rats.{17364,15762} AM3102 demonstrates weak affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with Ki values of 33 and 26 µM, respectively.{7422}
Brand:CaymanSKU:- Oleoyl ethanolamide (OEA) is an endogenous agonist for proliferator-activated receptor α (PPARα) that suppresses food intake, promotes lipolysis, and reduces weight gain in rodents. The biological effects of OEA are terminated by fatty-acid amide hydrolase and N-acylethanolamine-hydrolyzing acid amidase. AM3102 is an OEA analog that stimulates PPARα transcriptional activity with an EC50 value of 100 nM and prolongs feeding latency in rodents with an ED50 value of 2.4 mg/kg.{17364} It is resistant to enzymatic hydrolysis and is as potent as OEA in enhancing transcriptional activity of PPARα and reducing food intake in free-feeding rats.{17364,15762} AM3102 demonstrates weak affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with Ki values of 33 and 26 µM, respectively.{7422}
Brand:CaymanSKU:-
AM404 is an analog of arachidonyl ethanolamide (AEA) which potentiates the activity of endogenous AEA by blocking its re-uptake into presynaptic neurons. AM404 selectively inhibits the carrier-mediated transport of AEA without affecting anandamide hydrolysis. It inhibits the transport of AEA with an IC50 of 1 µM in rat neurons and 5 µM in rat astrocytes. In in vivo models, AM404 enhances and prolongs exogenous AEA-induced analgesia at a dose of 10 mg/kg.{4894}
Brand:CaymanSKU:90060 - 10 mgAvailable on backorder
AM404 is an analog of arachidonyl ethanolamide (AEA) which potentiates the activity of endogenous AEA by blocking its re-uptake into presynaptic neurons. AM404 selectively inhibits the carrier-mediated transport of AEA without affecting anandamide hydrolysis. It inhibits the transport of AEA with an IC50 of 1 µM in rat neurons and 5 µM in rat astrocytes. In in vivo models, AM404 enhances and prolongs exogenous AEA-induced analgesia at a dose of 10 mg/kg.{4894}
Brand:CaymanSKU:90060 - 100 mgAvailable on backorder
AM404 is an analog of arachidonyl ethanolamide (AEA) which potentiates the activity of endogenous AEA by blocking its re-uptake into presynaptic neurons. AM404 selectively inhibits the carrier-mediated transport of AEA without affecting anandamide hydrolysis. It inhibits the transport of AEA with an IC50 of 1 µM in rat neurons and 5 µM in rat astrocytes. In in vivo models, AM404 enhances and prolongs exogenous AEA-induced analgesia at a dose of 10 mg/kg.{4894}
Brand:CaymanSKU:90060 - 5 mgAvailable on backorder
AM404 is an analog of arachidonyl ethanolamide (AEA) which potentiates the activity of endogenous AEA by blocking its re-uptake into presynaptic neurons. AM404 selectively inhibits the carrier-mediated transport of AEA without affecting anandamide hydrolysis. It inhibits the transport of AEA with an IC50 of 1 µM in rat neurons and 5 µM in rat astrocytes. In in vivo models, AM404 enhances and prolongs exogenous AEA-induced analgesia at a dose of 10 mg/kg.{4894}
Brand:CaymanSKU:90060 - 50 mgAvailable on backorder
AM4113 is a cannabinoid receptor 1 (CB1)-selective neutral antagonist that binds to CB1 and CB2 with Ki values of 0.89 and 92 nM, respectively.{32595} In rats, it has been shown to reduce food intake and food-reinforced behavior, such as time spent feeding, thereby reducing weight gain without inducing nausea.{32594} This compound has also been used to study the abuse-related effects of nicotine, as well as the effects of nicotine on anxiety and depressive-like behavior in rats.{32593}
Brand:CaymanSKU:20581 -Available on backorder
AM4113 is a cannabinoid receptor 1 (CB1)-selective neutral antagonist that binds to CB1 and CB2 with Ki values of 0.89 and 92 nM, respectively.{32595} In rats, it has been shown to reduce food intake and food-reinforced behavior, such as time spent feeding, thereby reducing weight gain without inducing nausea.{32594} This compound has also been used to study the abuse-related effects of nicotine, as well as the effects of nicotine on anxiety and depressive-like behavior in rats.{32593}
Brand:CaymanSKU:20581 -Available on backorder
AM4113 is a cannabinoid receptor 1 (CB1)-selective neutral antagonist that binds to CB1 and CB2 with Ki values of 0.89 and 92 nM, respectively.{32595} In rats, it has been shown to reduce food intake and food-reinforced behavior, such as time spent feeding, thereby reducing weight gain without inducing nausea.{32594} This compound has also been used to study the abuse-related effects of nicotine, as well as the effects of nicotine on anxiety and depressive-like behavior in rats.{32593}
Brand:CaymanSKU:20581 -Available on backorder
AM4113 is a cannabinoid receptor 1 (CB1)-selective neutral antagonist that binds to CB1 and CB2 with Ki values of 0.89 and 92 nM, respectively.{32595} In rats, it has been shown to reduce food intake and food-reinforced behavior, such as time spent feeding, thereby reducing weight gain without inducing nausea.{32594} This compound has also been used to study the abuse-related effects of nicotine, as well as the effects of nicotine on anxiety and depressive-like behavior in rats.{32593}
Brand:CaymanSKU:20581 -Available on backorder
AM580 is a retinoic acid receptor agonist that is selective for RARα (Kd = 8 nM; AC50 = 0.36 nM) compared to RARβ (Kd = 131 nM; AC50 = 24.6 nM) and RARγ (Kd = 450 nM; AC50 = 27.9 nM).{24736} It demonstrates greater specific binding to RARα compared to retinoic acid (Item No. 11017), which exhibits little selectivity across RARα, β, or γ.{24736,18516,20156} AM580 has been used in combination with the GSK3β inhibitor CHIR99021 (Item No. 13122) to efficiently induce differentiation of human induced pluripotent stem cells into immediate mesoderm.{25645} It can also inhibit the proliferation of various tumor cells, inhibiting survival signaling pathways and inducing apoptosis.{25647,25646}
Brand:CaymanSKU:- AM580 is a retinoic acid receptor agonist that is selective for RARα (Kd = 8 nM; AC50 = 0.36 nM) compared to RARβ (Kd = 131 nM; AC50 = 24.6 nM) and RARγ (Kd = 450 nM; AC50 = 27.9 nM).{24736} It demonstrates greater specific binding to RARα compared to retinoic acid (Item No. 11017), which exhibits little selectivity across RARα, β, or γ.{24736,18516,20156} AM580 has been used in combination with the GSK3β inhibitor CHIR99021 (Item No. 13122) to efficiently induce differentiation of human induced pluripotent stem cells into immediate mesoderm.{25645} It can also inhibit the proliferation of various tumor cells, inhibiting survival signaling pathways and inducing apoptosis.{25647,25646}
Brand:CaymanSKU:- AM580 is a retinoic acid receptor agonist that is selective for RARα (Kd = 8 nM; AC50 = 0.36 nM) compared to RARβ (Kd = 131 nM; AC50 = 24.6 nM) and RARγ (Kd = 450 nM; AC50 = 27.9 nM).{24736} It demonstrates greater specific binding to RARα compared to retinoic acid (Item No. 11017), which exhibits little selectivity across RARα, β, or γ.{24736,18516,20156} AM580 has been used in combination with the GSK3β inhibitor CHIR99021 (Item No. 13122) to efficiently induce differentiation of human induced pluripotent stem cells into immediate mesoderm.{25645} It can also inhibit the proliferation of various tumor cells, inhibiting survival signaling pathways and inducing apoptosis.{25647,25646}
Brand:CaymanSKU:- AM580 is a retinoic acid receptor agonist that is selective for RARα (Kd = 8 nM; AC50 = 0.36 nM) compared to RARβ (Kd = 131 nM; AC50 = 24.6 nM) and RARγ (Kd = 450 nM; AC50 = 27.9 nM).{24736} It demonstrates greater specific binding to RARα compared to retinoic acid (Item No. 11017), which exhibits little selectivity across RARα, β, or γ.{24736,18516,20156} AM580 has been used in combination with the GSK3β inhibitor CHIR99021 (Item No. 13122) to efficiently induce differentiation of human induced pluripotent stem cells into immediate mesoderm.{25645} It can also inhibit the proliferation of various tumor cells, inhibiting survival signaling pathways and inducing apoptosis.{25647,25646}
Brand:CaymanSKU:-
AM630 binds selectively to cannabinoid 2 (CB2) over CB1 receptors with Ki values of 31.2 and 5,152 nM, respectively.{13044} AM630 acts as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors.{13044,14986,16701} It decreases proliferation and induces arrest of the cell cycle at the G2/M phase in renal cell carcinoma cells.{38338}
Brand:CaymanSKU:10006974 - 10 mgAvailable on backorder
AM630 binds selectively to cannabinoid 2 (CB2) over CB1 receptors with Ki values of 31.2 and 5,152 nM, respectively.{13044} AM630 acts as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors.{13044,14986,16701} It decreases proliferation and induces arrest of the cell cycle at the G2/M phase in renal cell carcinoma cells.{38338}
Brand:CaymanSKU:10006974 - 100 mgAvailable on backorder
AM630 binds selectively to cannabinoid 2 (CB2) over CB1 receptors with Ki values of 31.2 and 5,152 nM, respectively.{13044} AM630 acts as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors.{13044,14986,16701} It decreases proliferation and induces arrest of the cell cycle at the G2/M phase in renal cell carcinoma cells.{38338}
Brand:CaymanSKU:10006974 - 5 mgAvailable on backorder
AM630 binds selectively to cannabinoid 2 (CB2) over CB1 receptors with Ki values of 31.2 and 5,152 nM, respectively.{13044} AM630 acts as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors.{13044,14986,16701} It decreases proliferation and induces arrest of the cell cycle at the G2/M phase in renal cell carcinoma cells.{38338}
Brand:CaymanSKU:10006974 - 50 mgAvailable on backorder
Peripherally-restricted cannabinoid receptor 1 (CB1) selective antagonists have the potential to inhibit food intake while also escaping centrally-mediated neuropsychiatric side effects. AM6545 is a novel CB1 selective neutral antagonist with low CNS penetration, exhibiting Ki values of 1.7 and 523 nM for CB1 and CB2 receptors, respectively.{28438} It reduces food intake and food-reinforced behavior, such as time spent feeding, in a dose-dependent manner, resulting in decreased body weight.{28438,28439} AM6545 produces improvements in glucose homeostasis, fatty liver, and plasma lipid profiles in mice with diet-induced obesity.{28440} It does not affect behavior responses that are associated with activation of CB1 receptors in the brain.{28440}
Brand:CaymanSKU:-Out of stock
Peripherally-restricted cannabinoid receptor 1 (CB1) selective antagonists have the potential to inhibit food intake while also escaping centrally-mediated neuropsychiatric side effects. AM6545 is a novel CB1 selective neutral antagonist with low CNS penetration, exhibiting Ki values of 1.7 and 523 nM for CB1 and CB2 receptors, respectively.{28438} It reduces food intake and food-reinforced behavior, such as time spent feeding, in a dose-dependent manner, resulting in decreased body weight.{28438,28439} AM6545 produces improvements in glucose homeostasis, fatty liver, and plasma lipid profiles in mice with diet-induced obesity.{28440} It does not affect behavior responses that are associated with activation of CB1 receptors in the brain.{28440}
Brand:CaymanSKU:-Out of stock
Peripherally-restricted cannabinoid receptor 1 (CB1) selective antagonists have the potential to inhibit food intake while also escaping centrally-mediated neuropsychiatric side effects. AM6545 is a novel CB1 selective neutral antagonist with low CNS penetration, exhibiting Ki values of 1.7 and 523 nM for CB1 and CB2 receptors, respectively.{28438} It reduces food intake and food-reinforced behavior, such as time spent feeding, in a dose-dependent manner, resulting in decreased body weight.{28438,28439} AM6545 produces improvements in glucose homeostasis, fatty liver, and plasma lipid profiles in mice with diet-induced obesity.{28440} It does not affect behavior responses that are associated with activation of CB1 receptors in the brain.{28440}
Brand:CaymanSKU:-Out of stock
Peripherally-restricted cannabinoid receptor 1 (CB1) selective antagonists have the potential to inhibit food intake while also escaping centrally-mediated neuropsychiatric side effects. AM6545 is a novel CB1 selective neutral antagonist with low CNS penetration, exhibiting Ki values of 1.7 and 523 nM for CB1 and CB2 receptors, respectively.{28438} It reduces food intake and food-reinforced behavior, such as time spent feeding, in a dose-dependent manner, resulting in decreased body weight.{28438,28439} AM6545 produces improvements in glucose homeostasis, fatty liver, and plasma lipid profiles in mice with diet-induced obesity.{28440} It does not affect behavior responses that are associated with activation of CB1 receptors in the brain.{28440}
Brand:CaymanSKU:-Out of stock
AM679 is a potent synthetic cannabinoid (CB) with Ki values of 13.5 and 49.5 nM for the CB1 and CB2 receptors, respectively.{18696} The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications.
Brand:CaymanSKU:11504 - 10 mgAvailable on backorder
AM679 is a potent synthetic cannabinoid (CB) with Ki values of 13.5 and 49.5 nM for the CB1 and CB2 receptors, respectively.{18696} The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications.
Brand:CaymanSKU:11504 - 25 mgAvailable on backorder
AM679 is a potent synthetic cannabinoid (CB) with Ki values of 13.5 and 49.5 nM for the CB1 and CB2 receptors, respectively.{18696} The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic applications.
Brand:CaymanSKU:11504 - 5 mgAvailable on backorder
AM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.{18696} The physiological actions and metabolism of AM694 have not been characterized.
Brand:CaymanSKU:-
AM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.{18696} AM694 3-iodo isomer is an analog of AM694 which contains a 3-iodophenyl group linked by methanone to the indole base. Its affinity for CB receptors has not been determined. This compound is intended for forensic applications.
Brand:CaymanSKU:10870 - 1 mgAvailable on backorder
AM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.{18696} AM694 3-iodo isomer is an analog of AM694 which contains a 3-iodophenyl group linked by methanone to the indole base. Its affinity for CB receptors has not been determined. This compound is intended for forensic applications.
Brand:CaymanSKU:10870 - 10 mgAvailable on backorder
AM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.{18696} AM694 3-iodo isomer is an analog of AM694 which contains a 3-iodophenyl group linked by methanone to the indole base. Its affinity for CB receptors has not been determined. This compound is intended for forensic applications.
Brand:CaymanSKU:10870 - 5 mgAvailable on backorder
AM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.{18696} AM694 4-iodo isomer is an analog of AM694 which contains a 4-iodophenyl group linked by methanone to the indole base. Its affinity for CB1 and CB2 receptors has not been determined. The pharmacological, physiological, and toxicological properties of AM694 4-iodo isomer are not known.
Brand:CaymanSKU:10869 - 1 mgAvailable on backorder
AM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.{18696} AM694 4-iodo isomer is an analog of AM694 which contains a 4-iodophenyl group linked by methanone to the indole base. Its affinity for CB1 and CB2 receptors has not been determined. The pharmacological, physiological, and toxicological properties of AM694 4-iodo isomer are not known.
Brand:CaymanSKU:10869 - 10 mgAvailable on backorder
AM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.{18696} AM694 4-iodo isomer is an analog of AM694 which contains a 4-iodophenyl group linked by methanone to the indole base. Its affinity for CB1 and CB2 receptors has not been determined. The pharmacological, physiological, and toxicological properties of AM694 4-iodo isomer are not known.
Brand:CaymanSKU:10869 - 5 mgAvailable on backorder
AM694 (Item No. 10567) is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM694 N-(5-hydroxypentyl) metabolite is an expected urinary metabolite of AM694, based on the known metabolism of similar compounds.{19353} Its biological actions are unknown. This product is intended for forensic and research applications.
Brand:CaymanSKU:- AM694 (Item No. 10567) is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM694 N-(5-hydroxypentyl) metabolite is an expected urinary metabolite of AM694, based on the known metabolism of similar compounds.{19353} Its biological actions are unknown. This product is intended for forensic and research applications.
Brand:CaymanSKU:- AM694 (Item No. 10567) is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM694 N-(5-hydroxypentyl) metabolite is an expected urinary metabolite of AM694, based on the known metabolism of similar compounds.{19353} Its biological actions are unknown. This product is intended for forensic and research applications.
Brand:CaymanSKU:-
AM694 (Item No. 10567) is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM694 N-pentanoic acid metabolite is a potential phase I metabolite of AM694, based on the known metabolism of similar compounds.{19353} The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research applications.
Brand:CaymanSKU:- AM694 (Item No. 10567) is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM694 N-pentanoic acid metabolite is a potential phase I metabolite of AM694, based on the known metabolism of similar compounds.{19353} The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research applications.
Brand:CaymanSKU:- AM694 (Item No. 10567) is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the central CB1 and peripheral CB2 receptors, respectively.{18696} AM694 N-pentanoic acid metabolite is a potential phase I metabolite of AM694, based on the known metabolism of similar compounds.{19353} The physiological and toxicological properties of this compound have not been evaluated. This product is intended for forensic and research applications.
Brand:CaymanSKU:-
AM80 is a retinoic acid receptor agonist that is selective for RARα (Kd = 62 nM; AC50 = 1.46 nM) compared to RARβ (Kd = 280 nM; AC50 = 6.87 nM) and RARγ (Kd = 816 nM; AC50 = 148.7 nM).{24736} It demonstrates greater specific binding to RARα compared to retinoic acid (Item No. 11017), which exhibits little selectivity across RARα, β, or γ.{25644,24736} AM80 exhibits antiproliferative effects against acute promyelocytic leukemia cells, inducing human promyelocytic leukemia HL-60 cell differentiation with an ED50 value of 0.79 nM.{23266,25644} It has also been shown to suppress the growth of other myeloid and lymphoid malignant cells.{25644}
Brand:CaymanSKU:71770 - 10 mgAvailable on backorder